<DOC>
	<DOCNO>NCT01936324</DOCNO>
	<brief_summary>The purpose study determine safety tolerability DRM01B topical healthy volunteer . Following review safety data , study determine safety , tolerability preliminary efficacy DRM01B Topical Gel subject acne vulgaris</brief_summary>
	<brief_title>A Safety , Tolerability Preliminary Efficacy Study DRM01B Topical Gel</brief_title>
	<detailed_description>This Phase 1/2a study enrol 6 healthy volunteer subject follow 100 subject acne vulgaris . Safety data healthy volunteer stage review prior enrol subject acne vulgaris . Phase 1 open label study design ass safety tolerability DRM01B Topical Gel . Six ( 6 ) healthy volunteer enrol apply DRM01B gel 1 week face . Adverse event local tolerability assess study visit . Phase 2a randomize , vehicle control , parallel group study design assess safety , tolerability preliminary efficacy DRM01B topical gel subject acne vulgaris . Approximately 100 subject enrol treated study drug 12 week . Safety assess , specify time point study , adverse event , local skin response , serum chemistry hematology laboratory testing , physical examination vital sign . Preliminary efficacy assess lesion count ( e.g. , inflammatory , noninflammatory ) Investigator Global Assessment ( IGA ) acne .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Key 1 . Signed informed consent 2 . Willing comply requirement protocol . 3 . Male nonpregnant , nonlactating female 4 . Age ≥ 18 year 5 . Clinical diagnosis facial acne vulgaris define : At least 20 inflammatory lesion At least 20 noninflammatory lesion Investigator Global Assessment 3 great 6 . Willing refrain use treatment , investigational product , include antibiotic , acne present face . Topical acne treatment significant measurable systemic absorption ( e.g. , benzoyl peroxide , salicylic acid ) allow treatment acne back , shoulder chest . Key 1 . Females pregnant , plan become pregnant course study , breastfeed . 2 . Any skin condition may interfere evaluation safety acne vulgaris ( e.g. , rosacea ; seborrheic dermatitis ; perioral dermatitis ; corticosteroidinduced acne folliculitis ) 3 . Excessive facial hair would interfere diagnosis assessment acne vulgaris . 4 . Excessive sun exposure , opinion investigator , use tan booth . 5 . Active cystic acne acne congoblata , acne fulminans , secondary acne 6 . Two active nodular lesion 7 . Treatment overthecounter topical medication treatment acne vulgaris include benzoyl peroxide , topical antiinflammatory medication , corticosteroid , αhydroxy/glycolic acid face within 2 week prior baseline . 8 . Treatment systemic corticosteroid ( include intranasal inhaled corticosteroid ) within 4 week prior baseline 9 . Treatment systemic antibiotic systemic antiacne drug systemic antiinflammatory drug within 4 week prior baseline 10 . Prescription topical retinoid use face within 4 week baseline ( e.g. , tretinoin , tazarotene , adapalene ) . 11 . Treatment hormonal therapy dose change hormonal therapy within 12 week prior baseline . Dose frequency use hormonal therapy start 12 week prior baseline must remain unchanged throughout study . Hormonal therapy include , limited , estrogenic progestational agent birth control pill . 12 . Use androgen receptor blocker ( spironolactone flutamide ) 13 . Oral retinoid use ( e.g. , isotretinoin ) within 12 month prior baseline vitamin A supplement great 10,000 units/day within 6 month baseline . 14 . Facial procedure ( chemical laser peel , microdermabrasion , etc . ) within past 8 week study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>acne vulgaris</keyword>
</DOC>